NTRA Natera, Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
11:50
Oct 03
Oct 03
Chesley Investment Advisory
NGS demand rising; buy sequencing equipment.
NGS (next-generation sequencing) demand is rising strongly, led by Illumina, Natera, and Tempus. ASPs are increasing, penetration is still low, and fundamentals are good, making it a strong biotech equipment area.
NTRA
Natera, Inc. Common Stock
Long
1ST
—
—
08:30
Jul 19
Jul 19
815 Money Talk
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
NTRA
Natera, Inc. Common Stock
Long
1ST
—
—
18:49
Jan 07
Jan 07
CNBC
Natera leads women's health mid-market
She added to Natera because she is a big believer in women's health, and she thinks the company owns the mid-market, is growing earnings double digits, and has significantly improved gross margins from roughly 40% to 60% a decade ago.
NTRA
Natera, Inc. Common Stock
Long
1ST
—
—
About NTRA Investor Commentary
Across the available history and selected sources, Buzzberg tracks NTRA (Natera, Inc. Common Stock) across 8 sources: 4 bullish vs 0 bearish calls from 11 authors. Historical directional balance: 22% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 18 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Shin Woo-young, Choi Chang-gyu, Stephanie Link.